OHR Pharmaceutical Inc (NASDAQ:OHRP) said its experimental eye drop showed no significant benefit over a placebo in reducing the number of injections of another drug directly into the eye, but improved patients’ visual clarity.OHR Pharmaceutical Inc (NASDAQ:OHRP) weekly performance is -16.95%. On last trading day company shares ended up $7.74. Analysts mean target price for the company is $21.00. OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average is -14.11%.
The CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. CytRx Corporation (NASDAQ:CYTR) shares fell -6.88% in last trading session and ended the day on $4.33. CYTR its return on assets is -68.30%. CytRx Corporation (NASDAQ:CYTR) quarterly performance is 17.34%.
StemCells Inc (STEM) is surging today on the news of the company’s lead drug HuCNS-SC showing strong results in a phase 1/2 trial for treating macular degeneration (AMD). The company announced the results yesterday at the International Society for Stem Cell Research. AMD impairs visual functions and has become the major cause of blindness in adults over the age of 55. The disease is estimated to affect about 10 million people in the US who are over the age of 50.StemCells Inc (NASDAQ:STEM) shares moved down -6.12% in last trading session and was closed at $1.84, while trading in range of $1.82-$1.98. StemCells Inc (NASDAQ:STEM) year to date performance is 49.59%.
The Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that the Company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, at 2:30 p.m. (EDT) in New York. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) ended the last trading day at $4.23. Company weekly volatility is calculated as 3.14% and price to cash ratio as 5.01. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) showed a negative weekly performance of -2.08%.
CEL-SCI Corp. (AMEX: CVM) announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014.CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is 4.46%. On last trading day company shares ended up $1.17. Analysts mean target price for the company is $7.00. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average is 1.18%.